Sickle cell disease trials recruiting in Michigan

All Sickle cell disease trials nationally

Cities in Michigan

Recruiting trials in Michigan

• A Long-term Follow-up Study in Patients Who Received BEAM-101
  NCT07373639 · Phase: Not specified · Ages: 14 Years to 37 Years · Sex: All (male and female) · Michigan: Detroit
• A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
  NCT05431088 · Phase: Phase 2, Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · Michigan: Detroit, Southfield
• A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
  NCT06612268 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · Michigan: Detroit
• A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
  NCT07656415 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · Michigan: Grand Rapids
• ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
  NCT04398628 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Michigan: Detroit
• Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)
  NCT06071377 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Detroit
• HPC Offered for PRESERVE Expansion
  NCT07145411 · Phase: Not specified · Ages: 12 Years to 80 Years · Sex: All (male and female) · Michigan: Detroit
• Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
  NCT06374238 · Phase: Not applicable (e.g. observational or device study) · Ages: 16 Years to 30 Years · Sex: All (male and female) · Michigan: Ann Arbor
• Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
  NCT03128996 · Phase: Phase 1, Phase 2 · Ages: 1 Day to 21 Years · Sex: All (male and female) · Michigan: Grand Rapids
• Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
  NCT06699849 · Phase: Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · Michigan: Detroit
• The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
  NCT06975865 · Phase: Phase 3 · Ages: 10 Years to 65 Years · Sex: All (male and female) · Michigan: Ann Arbor